N@N

BETHESDA, Md.--([ BUSINESS WIRE ])--[ Sucampo ] Pharmaceuticals, Inc. (NASDAQ: SCMP) announced that the hearing on the Companyas claims in the demand for arbitration under the applicable provisions of the Collaboration and License Agreement with Takeda Pharmaceuticals Company Limited, or Takeda, dated October 29, 2004, have concluded within the expected timeframe and we look forward to the arbitratorsa decision in the first quarter of 2012.

Under the current agreement, Sucampo and Takeda jointly commercialize AMITIZA (lubiprostone) in the United States for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) and are developing AMITIZA for other gastrointestinal indications.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company, focuses on the development and commercialization of medicines based on [ prostones ]. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticalsa Chairman and CEO. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with [ Sachiko Kuno ], Ph.D., founding CEO and currently Executive Advisor, International Business Development and a member of the Board of Directors. For more information about Sucampo Pharmaceuticals, please visit [ www.sucampo.com ].

Forward-Looking Statement

Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words aproject,a abelieve,a aanticipate,a aplan,a aexpect,a aestimate,a aintend,a ashould,a awould,a acould,a awill,a amaya or other similar expressions. Forward-looking statements include statements about the potential utility of AMITIZA and RESCULA to treat particular indications and expected data availability dates. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in Sucampo Pharmaceuticalsa filings with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K for the year ended December 31, 2010 and other periodic reports filed with the SEC. Any forward-looking statements in this press release represent Sucampo Pharmaceuticalsa views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, Sucampo Pharmaceuticals specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.